Bacterial vaccines fight against antimicrobial resistance

A biotech in the UK has out-licensed a C. difficile candidate to a US biotech for further clinical and commercialization efforts. UK-based Destiny Pharma announced Friday that it is handing NTCD-M3 to Sebela Pharmaceuticals. The deal includes an initial $1 million upfront, $19 million in development milestones, and an additional

Engineered microbes show potential for diagnosing and treating diseases. In this issue of Cell Host & Microbe, Zou et al. develop an “intelligent” bac…

Contagion® is a fully integrated news resource for practitioners and specialists to assist with the identification, diagnosis, treatment, and prevention of infectious diseases.

Medical News and articles you can trust from around the world. All content is written and reviewed by qualified health, medical and scientific experts.

https://www.youtube.com/watch?v=ZAUw0Sh7tyc

Endospore-forming bacteria are ubiquitous, and their endospores can be present in food, in domestic animals, and on contaminated surfaces. Many spore-forming bacteria have been used in biotechnological applications, while others are human pathogens responsible for a wide range of critical clinical i …

Clostridioides difficile (CD) is a Gram-positive, anaerobic bacterium that infects mainly hospitalized and elderly people who have been treated with long-term antibiotic therapy leading to dysbiosis. The deteriorating demographic structure and the increase in the number of antibiotics used in …

The rising burden of antimicrobial resistance and increasing infectious disease outbreaks, including the recent COVID-19 pandemic, has led to a growing demand for the development of natural products as a valuable source of leading medicinal compounds. There is a wide variety of active constituents f …

Clostridioides difficile infection (CDI) is an urgent threat and unmet medical need. The current treatments for CDI are not enough to fight the burden of CDI and recurrent CDI (r-CDI). This review aims to highlight the future drugs for CDI and their related patented applications. The non-pate …

Clostridioides difficile (CD) is a Gram-positive, anaerobic bacterium that infects mainly hospitalized and elderly people who have been treated with long-term antibiotic therapy leading to dysbiosis. The deteriorating demographic structure and the increase in the number of antibiotics used in …

Destiny Pharma has signed an exclusive collaboration and co-development agreement for the North American rights of NTCD-M3, its medicine to prevent...

A New Gold Standard for C. diff Therapy Could be in the Offing;  Next Data Release Expected in 2Q23

Nature Reviews Microbiology - This Genome Watch explores how large-scale microbiome studies are facilitating discoveries in bacteriophage biology and functional capabilities that are prime for...

Bacterial vaccines fight against antimicrobial resistance

Learn about our ongoing C. diff treatment trial: a randomized, double-blind evaluation of CRS3123 vs. Oral Vancomycin for adults with C. difficile Infection.

This phase 3, open-label, single-arm trial assesses the safety of SER-109 and the rate of recurrent Clostridioides difficile infection after administration of SER-109 following symptom resolution after antibiotic treatment among adults.

There's good news, and then there's excellent news. The good news is that Acurx Pharmaceuticals is nearing its Phase 3 trial to get a best-in-class front-line treatment for C. difficile to the... | February 21, 2023

Researchers investigated the tolerability and safety of a microbiome therapy called SER-109 to treat recurrent infections of Clostridioides difficile in adults.

Crystal structures of camelid heavy-chain antibody variable domains (VHHs) bound to fragments of the combined repetitive oligopeptides domain of Clostridiodes difficile toxin A (TcdA) reveal that the C-terminus of VHH A20 was located 30 Å away from the N-terminus of V …

SER-109, an investigational microbiome therapeutic for treating recurrent Clostridioides difficile infection, was well tolerated and showed clinical benefit.

Acurx Pharmaceuticals' (NASDAQ:ACXP) mission in bringing to market an effective and durable treatment for C. difficile was provided a significant step forward. This time, it came as a result of yet another Phase 3

ClinicalTrials.gov identifier: NCT03183141.

Acurx Pharmaceuticals' mission in bringing to market an effective and durable treatment for C. difficile was provided a significant step forward. This time, it came as a result of yet another Phase... | February 8, 2023